Abstract
To clarify the possible role of DCC gene alteration in ovarian neoplasias, we immunohistochemically investigated 124 carcinomas, as well as 55 cystadenomas and 41 low malignant potential (LMP) tumours and compared the results with those for p53 protein expression, clinicopathological factors and survival. A combination of the reverse transcription polymerase chain reaction (RT-PCR) and Southern blot hybridization (SBH) for DCC mRNA levels was also carried out on 26 malignant, five LMP, eight benign and seven normal ovarian samples. Significantly decreased levels of overall DCC values in carcinomas compared with benign and LMP lesions were revealed by both immunohistochemical and RT-PCR/SBH assays. Similar findings were also noted when subdivision was into serous and mucinous categories. In carcinomas, reduction or loss of DCC expression was significantly related to the serous phenotype (serous vs non-serous, P< 0.0001), a high histological grade (grade 1 vs 2 or 3, P< 0.02) and a more advanced stage (FIGO stage I vs II/III/IV, P = 0.0083), while no association was noted with survival. Although p53 immunopositivity demonstrated significant stepwise increase from benign through to malignant lesions, there was no clear association with DCC score values. The results indicated that impaired DCC expression may play an important role in ovarian tumorigenesis. In ovarian carcinomas, the altered expression is closely linked with tumour differentiation and progression. © 2000 Cancer Research Campaign
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Baas IO, Mulder J-WR, Offerhaus JA, Vogelstein B and Hamilton SR (1994) An evaluation of six antibodies for immunohistochemistry of mutant p53 gene product in archival colorectal neoplasms. J Pathol 172: 5–12
Bell DA and Scully RE (1994) Early de novo ovarian carcinoma: a study of fourteen cases. Cancer 73: 1859–1864
Cho KR, Oliner JD, Simons JW, Hedrick L, Fearon ER, Preisinger AC, Hedge P, Silverman GA and Vogelstein B (1994) The DCC gene: structural analysis and mutations in colorectal carcinomas. Genomics 19: 525–531
Chuong C-M, Jiang T-X, Yin E and Widelitz RB (1994) cDCC (chicken homologue to a gene deleted in colorectal carcinoma) is an epithelial adhesion molecule expressed in the basal cells and involved in epithelial–mesenchymal interaction. Dev Biol 164: 383–397
DiSaia PJ and Creasman WT (1993) Borderline malignant epithelial ovarian cancer. In: Clinical Gynecologic Oncology, Manning S (ed) pp. 320–323. Mosby-Year Book: St Louis
Ekstrand BC, Mansfield TA, Bigner SH and Fearon ER (1995) DCC expression is altered by multiple mechanisms in brain tumours. Oncogene 11: 2393–2402
Eltabbakh GH, Belinson JL, Kennedy AW, Biscotti CV, Casey G, Tubbs RR and Blumenson LE (1997) p53 overexpression is not an independent prognostic factor for patients with primary ovarian epithelial cancer. Cancer 80: 892–898
Enomoto T, Fujita M, Cheng C, Nakashima R, Ozaki M, Inoue M and Nomura T (1995) Loss of expression and loss of heterozygosity in the DCC gene in neoplasms of the human female reproductive tract. Br J Cancer 71: 462–467
Fearon ER, Cho KR, Nigro JM, Kern SE, Simons JW, Ruppert JM, Hamilton SR, Preisinger AC, Thomas G, Kinzler KW and Vogelstein B (1990) Identification of a chromosome 18q gene that is altered in colorectal cancer. Science 247: 49–56
Gao X, Honn KV, Grignon D, Sakr W and Chen YQ (1993) Frequent loss of expression and loss of heterozygosity of the putative tumor suppressor gene DCC in prostatic carcinomas. Cancer Res 53: 2723–2727
Goi T, Yamaguchi A, Nakagawara G, Urano T, Shiku H and Furukawa K (1998) Reduced expression of deleted colorectal carcinoma (DCC) protein in established colon cancers. Br J Cancer 77: 466–471
Hedrick L, Cho KR, Fearon ER, Wu T-C, Kinzler KW and Vogelstein B (1994) The DCC gene product in cellular differentiation and colorectal tumorigenesis. Genes Dev 8: 1174–1183
Herod JJO, Eliopoulos AG, Warwick J, Niedobitek G, Young LS and Kerr DJ (1996) The prognostic significance of bcl-2 and p53 expression in ovarian carcinoma. Cancer Res 56: 2178–2184
Horstmann MA, Posl M, Scholz RB, Anderegg B, Simon P, Baumgaertl K, Delling G and Kabisch H (1997) Frequent reduction or loss of DCC gene expression in human osteosarcoma. Br J Cancer 75: 1309–1317
Huang Y, Boynton RF, Blount PL, Silverstein RJ, Yin J, Tong Y, McDaniel TK, Newkirk C, Resau JH, Sridhara R, Reid BJ and Meltzer SJ (1992) Loss of heterozygosity involves multiple tumor suppressor genes in human esophageal cancers. Cancer Res 52: 6525–6530
Inoue M, Fujita M, Enomoto T, Morimoto H, Monden T, Shimano T and Tanizawa O (1994) Immunohistochemical analysis of p53 in gynecologic tumors. Am J Clin Pathol 102: 665–670
Keino-Masu K, Masu M, Hinck L, Leonardo ED, Chan SS-Y, Culotti JG and Tessier-Lavigne M (1996) Deleted in colorectal cancer (DCC) encodes a netrin receptor. Cell 87: 175–185
Kikuchi-Yanoshita R, Konishi M, Fukunari H, Tanaka K and Miyaki M (1992) Loss of expression of the DCC gene during progression of colorectal carcinomas in familial adenomatous polyposis and non-familial adenomatous polyposis patients. Cancer Res 52: 3801–3803
Klemi P-J, Takahashi S, Joensuu H, Kiilholma P, Narimatsu E and Mori M (1994) Immunohistochemical detection of p53 protein in borderline and malignant serous ovarian tumors. Int J Gyne Pathol 13: 228–233
Klemi P-J, Pylkkanen L, Kiilholma P, Kurvinen K and Joensuu H (1995) p53 protein detected by immunohistochemistry as a prognostic factor in patients with epithelial ovarian carcinoma. Cancer 76: 1201–1208
Klingelhutz AJ, Hedrick L, Cho KR and McDougall JK (1995) The DCC gene suppresses the malignant phenotype of transformed human epithelial cells. Oncogene 10: 1581–1586
Kong X-T, Choi SH, Inoue A, Xu F, Chen T, Takita J, Yokota J, Bessho F, Yanagisawa M, Hanada R, Yamamoto K and Hayashi Y (1997) Expression and mutational analysis of the DCC, DPC4, and MADR2/JV18-1 genes in neuroblastoma. Cancer Res 57: 3772–3778
Maestro R, Dolcetti R, Gasparotto D, Doglioni C, Pelucchi S, Barzan L, Grandi E and Boiocchi M (1992) High frequency of p53 gene alterations associated with protein overexpression in human squamous cell carcinoma of the larynx. Oncogene 7: 1159–1166
Maesawa C, Tamura G, Suzuki Y, Ogasawara S, Sakata K, Kashiwaba M and Satodate R (1995) The sequential accumulation of genetic alterations characteristic of the colorectal adenoma–carcinoma sequence does not occur between gastric adenoma and adenocarcinoma. J Pathol 176: 249–258
Mandai M, Konishi I, Kuroda H, Komatsu T, Yamamoto S, Nanbu K, Matsushita K, Fukumoto M, Yamabe H and Mori T (1998) Heterogeneous distribution of K-ras-mutated epithelia in mucinous ovarian tumors with special reference to histopathology. Hum Pathol 28: 34–40
Reale MA, Hu G, Zafar AI, Getzenberg RH, Levine SM and Fearon ER (1994) Expression and alternative splicing of the deleted in colorectal cancer (DCC) gene in normal and malignant tissues. Cancer Res 54: 4493–4501
Reles A, Schmider A, Press MF, Schonborn I, Huber-Schumacher WFS, Strohmeyer T and Lichtenegger W (1996) Immunostaining of p53 protein in ovarian carcinoma: correlation with histopathological data and clinical outcome. J Cancer Res Clin Oncol 122: 489–494
Reyes-Mugica M, Rieger-Christ K, Ohgaki H, Ekstrand BC, Helie M, Kleinman G, Yahanda A, Fearon ER, Kleihues P and Reale MA (1997) Loss of DCC expression and glioma progression. Cancer Res 57: 382–386
Saegusa M, Kamata Y, Isono M and Okayasu I (1996) Bcl-2 is correlated with a low apoptotic index and associated with progesterone receptor immunoreactivity in endometrial carcinomas. J Pathol 180: 275–282
Shibata D, Reale MA, Lavin P, Silverman M, Fearon ER, Steele G, Jr Jessup JM, Loda M and Summerhayes IC (1996) The DCC protein and prognosis in colorectal cancer. N Engl J Med 335: 1727–1732
Sinicrope FA, Ruan SB, Cleary KR, Stephens LC and Lee JJ (1995) bcl-2 and p53 oncoprotein expression during colorectal tumorigenesis. Cancer Res 55: 237–241
Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A and Press MF (1989) Studies of HER-2/ neu proto-oncogene in human breast and ovarian cancer. Science 244: 707–712
Uchino S, Tsuda H, Noguchi M, Yokota J, Terada M, Saito T, Kobayashi M, Sugimura T and Hirohashi S (1992) Frequent loss of heterozygosity at the DCC locus in gastric cancer. Cancer Res 52: 3099–3102
Wynford-Thomas D (1992) p53 in tumour pathology: can we trust immunohistochemistry?. J Pathol 166: 329–330
Zeimet AG, Widschwendter M, Uhl-Steidl M, Muller-Holzner E, Daxenbichler G, Marth C and Dapunt O (1997) High serum levels of soluble CD44 variant isoform v5 are associated with favourable clinical outcome in ovarian cancer. Br J Cancer 76: 1646–1651
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Saegusa, M., Machida, D. & Okayasu, I. Loss of DCC gene expression during ovarian tumorigenesis: relation to tumour differentiation and progression. Br J Cancer 82, 571–578 (2000). https://doi.org/10.1054/bjoc.1999.0966
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1054/bjoc.1999.0966
Keywords
This article is cited by
-
Lost expression of DCC gene in ovarian cancer and its inhibition in ovarian cancer cells
Medical Oncology (2011)